3D-Printed Reactor Fixes Protein Sugar Coats in Seconds

Modifying the sugar coats on therapeutic proteins usually takes hours in a single vessel, but a new benchtop reactor can attach key sugars to a protein in about 160 seconds. This setup addresses a major bottleneck in biotechnology, where manufacturing life-saving biologic drugs often yields proteins with incorrect or inconsistent sugar structures that can reduce their effectiveness or trigger immune reactions.

By bypassing the complex sugar-adding machinery inside living cells, this continuous-flow system allows scientists to build precise, human-like sugar structures on purified proteins after they have been produced. The research is published in Frontiers in Molecular Biosciences, detailing how the team designed and tested these specialized columns.

How the 3D-Printed Reactor Customizes Protein Sugar Coats

The research team, led by scientists including N. DeBono and E. Moh, built their system using small, 3D-printed plastic chambers. Inside these reactors, they immobilized specific human enzymes known as glycosyltransferases onto nickel-charged resin beads using a molecular tag. These enzymes act as microscopic assembly lines, adding individual sugar molecules onto passing proteins.

To test the setup, the authors used bovine fetuin, a blood protein rich in complex sugar chains, as a model substrate. They first stripped away certain terminal sugars from the protein to create a blank slate. When they pumped this modified protein through the enzyme-coated columns along with sugar building blocks, the reactor successfully added galactose and sialic acid groups to the protein’s surface within seconds.

The team tested two distinct enzyme reactors. One contained beta-1,4-galactosyltransferase, an enzyme that attaches galactose sugars, while the second contained alpha-2,6-sialyltransferase, which caps the sugar chains with sialic acid. Operating at a controlled temperature of 37 degrees Celsius inside a standard high-performance liquid chromatography oven, the columns demonstrated rapid conversion rates.

Measuring Flow Rates and Enzyme Longevity

The speed at which the protein solution flowed through the reactor directly influenced how completely the sugars were attached. Testing two different flow rates, 25 microliters per minute and 75 microliters per minute, revealed that the slower rate gave the enzymes more contact time with the protein, resulting in nearly complete galactosylation and substantial sialylation.

To evaluate reusability, the researchers ran repeated substrate injections through the columns over an eight-hour period. The galactosyltransferase reactor showed high initial activity that gradually decreased across the eight hours, while the sialyltransferase reactor maintained stable performance after an initial equilibration period. Mass spectrometry analysis confirmed that the immobilized enzymes retained their natural structural preferences, attaching sugars to specific molecular branches just as they would inside a living cell.

Overcoming Manufacturing Limitations in Biologics

Most therapeutic monoclonal antibodies and other biologic drugs are produced in mammalian cell lines such as Chinese hamster ovary cells. While these mammalian systems yield high quantities of protein, they frequently attach non-human or variable sugar structures that can cause rapid clearance from the bloodstream or adverse immune responses. Alternative production hosts like yeast, plants, or insect cells grow faster and cost less, but they produce incomplete or truncated sugar structures, making them unsuitable for many pharmaceutical applications.

The immobilized enzyme reactor decouples protein production from sugar modification. Manufacturers could potentially use cheap, robust expression systems to produce the protein backbone in large quantities, and then route the purified product through a series of these modular, plug-and-play reactors to finish the sugar structures with absolute precision. While the current proof-of-concept study utilized mammalian-expressed human enzymes and model proteins, the authors note that future iterations could incorporate more stable bacterial enzymes and be scaled up for industrial biomanufacturing.

The research was published in Frontiers in molecular biosciences on October 24, 2026.